SCHEMBL7187566

SCHEMBL7187566

COc1cc(Br)c(OC)c(C(=O)P(=O)(C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c2ccccc2)c1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.38
PDE7A Q13946 1/20 0.36
PDE3A Q14432 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7190542 0.90 LMNA (0.39) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7186868 0.88 POLB (0.38) LMNAMEN1KMT2AMAPTHPGD
SCHEMBL7180966 0.87 LMNA (0.43) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7722886 0.85 SLC6A9 (0.40) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7185490 0.84 LMNA (0.41) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7187560 0.84 ATM (0.41) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7174752 0.84 SMN1; SMN2 (0.41) LMNAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL7735676 0.83 CTSS (0.35) LMNAMEN1KMT2AMAPTHPGD
SCHEMBL7177059 0.83 SLC6A9 (0.45) LMNAMEN1KMT2ASMN1; SMN2HPGD
SCHEMBL7183742 0.82 HPGD (0.41) LMNAMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885MEN1 2312/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885MEN1 2263/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.